GSK's HIV prevention drug Approved by FDA
The US Food and Drug Administration(FDA) has approved GlaxoSmithKline’s HIV prevention injectable drug called Apretude. This is the first of its kind as before now drugs comparable to this were all oral tablets. The Hill reports that the drug, called will be available to at-risk adults and adolescents who weigh at least 77 pounds and have tested negative for HIV immediately beforehand. The agency’s endorsement opens up the alternative for patients to receive the injectable drug instead of daily HIV prevention oral medication, such as Truvada. Apretude instead requires two initiation injections, one month apart, and then shots every two months. The Hill further reports that two trials conducted across 13 countries determined that Apretude was more effective at preventing HIV infection than Truvada. Among more than 4,500 cisgender men and transgender women who have sex with men, participants who took the injectable medicine after the oral drug cabotegravir were 69 percent less ...
Comments
Post a Comment